Recombinant human erythropoietin improves neurological outcomes in very preterm infants

Abstract

Repeated low-dose rhEPO treatment reduced the risk of long-term neurological disability in very preterm infants with no obvious adverse effects. Ann Neurol 2016;80:24-34.